ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance mechanisms in cancer. The company’s pipeline centers on two lead product candidates: rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit, and enozertinib, a brain-penetrant, orally bioavailable, irreversible inhibitor targeting EGFR exon 20 and atypical mutations. Rinzimetostat is being evaluated in patients with metastatic castration-resistant prostate cancer, while enozertinib is being studied in non-small cell lung cancer patients with specific EGFR mutations. The company leverages expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to address innate, acquired, and bypass resistance. ORIC established its research and development platform in 2014 and has entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer to evaluate its drug candidates in combination with approved androgen receptor inhibitors. The company also maintains a license agreement with Mirati Therapeutics for rinzimetostat and a license and collaboration agreement with Voronoi Inc. for enozertinib.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage oricpharma.com
Sector Healthcare IR page investors.oricpharma.com
Tags
oncology, prostate cancer, non-small cell lung cancer, precision medicine, prc2 inhibitors, egfr inhibitors, clinical-stage, cancer resistance, Rinzimetostat, Enozertinib, ORIC-944, ORIC-114, Erleada, Nubeqa, apalutamide, darolutamide, amivantamab, Mirati Therapeutics, Voronoi Inc., Johnson & Johnson, Bayer Consumer Care AG
Press page —

Metrics

Valuation  
Market cap $ 1.405B
Market cap (USD) $ 1.405B
P/E -9.59
PEG —
P/BV 4.14
P/S —
P/OCF -10.93
P/FCF -10.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -41.3%
ROI -37.8%
ROIC -31.3%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 75
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 408.89M 274.142M 252.007M 247.178M 298.642M 298.997M 94.093M
Net profit -129.468M -127.847M -100.697M -89.122M -78.715M -73.703M -26.883M
Free cash flow -111.682M -113.85M -86.537M -77.221M -60.48M -45.935M -24.301M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 8.18 8.07 9.2 5.89 14.7 33.85 —
Price performance 12m 0.01 -0.12 0.56 -0.6 -0.57 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 0.00 1.93M 12.1M 10.2M 9.36M 7.44M
Cash and deposits (USD) 25.8M 42.6M 89.2M 78.4M 226M 66.8M 23.4M 59.4M 45.7M
Right-of-use assets (USD) — — — — 11.8M 11M 9.14M 8.38M 6.66M
Cash flow detail
Operating cash flow (USD) — -20.7M -23.5M -45.3M -59.5M -75.1M -85.7M -113M -111M
Purchases of property, plant and equipment (USD) — -525,000 -768,000 -667,000 -939,000 -2.08M -849,000 -1.19M -712,000
Change in payables (cash effect) (USD) — -410,000 986,000 4.3M 2.93M -1.48M 3.28M 1.83M -7.25M
Share-based compensation (USD) — 469,000 1.09M 5.28M 12.9M 14.5M 15.2M 20.2M 25M
Free cash flow (OCF - PPE - intangibles) (USD) — -21.2M -24.3M -45.9M -60.5M -77.2M -86.5M -114M -112M
Income detail
Research and development expense (USD) — 19M 22.8M 35.9M 56.9M 61.7M 85.2M 114M 110M
↳ 5y CAGR +35.0% +37.9% +25.0%
Total comprehensive income (USD) — -21.4M -26.9M -73.7M -78.8M -90.3M -99.1M -128M -129M
Comprehensive income to owners (USD) — -21.4M -26.9M -73.7M -78.8M -90.3M -99.1M -128M -129M
Reported Mar 23, 2021 Mar 23, 2021 Mar 23, 2021 Mar 21, 2022 Mar 21, 2022 Mar 16, 2023 Mar 11, 2024 Feb 18, 2025 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer

Provided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of landmark rPFS estimates in both populations that remain consistent with competitor PRC2 inhibitor, and reconfirming a highly differentiated safety profile

Presented potential best-in-class enozertinib data at ESMO Congress 2026, including 84% systemic ORR and 70% CNS ORR, setting a new benchmark in 1L EGFR atypical NSCLC

Announced Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027

Cash and investments of approximately $345 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat

SOUTH SAN FRANCISCO and SAN DIEGO, CA – November 16, 2026 – ORIC Pharmaceuticals, Inc.

PDF Version

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 2, 2026 (the “Grant Date”), ORIC granted a total of 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC’s product candidates; the potential advantages of ORIC’s product candidates; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

PDF Version

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:

  • Guggenheim’s 3rd Annual Healthcare Innovation Conference– Participating in a fireside chat on Tuesday, November 10, 2026, at 10:30 a.m. ET. Management will also be participating in one-on-one meetings.

  • Stifel 2026 Healthcare Conference– Participating in a fireside chat on Wednesday, November 11, 2026, at 2:00 p.m. ET. Management will also be participating in one-on-one meetings.

  • Jefferies London Healthcare Conference– Participating in a fireside chat on Wednesday, November 18, 2026, at 12:30 p.m. GMT. Management will also be participating in one-on-one meetings.

Webcasts of the fireside chat discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Prompts

Oric Pharmaceuticals, Inc. (ticker ORIC), listed in United States.

ETFs Holding Oric Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.61% 99,043 $ 1.287M Aug 31, 2026
TMED 0.21% 4,380 $ 47.435K Jun 30, 2026
ESSC 0.13% 4,173 $ 46.195K Jul 31, 2026
TMSL 0.11% 275,500 $ 2.984M Jun 30, 2026
FSEV 0.08% 490 $ 5,306.70 Jun 30, 2026
FESM 0.06% 299,096 $ 3.239M Jun 30, 2026
FSEG 0.05% 264 $ 2,859.12 Jun 30, 2026
AVSC 0.04% 174,177 $ 1.31M Nov 16, 2026
RESM 0.02% 73 $ 790.59 Jun 30, 2026
DFAS 0.02% 716,508 $ 6.09M Nov 12, 2026
DXUV 0.00% 30,220 $ 256.87K Nov 12, 2026
MSSM 0.00% 2,211 $ 28.721K Aug 31, 2026
DFAC 0.00% 398,933 $ 3.391M Nov 12, 2026
DCOR 0.00% 123,427 $ 1.049M Nov 12, 2026
DFAU 0.00% 25,914 $ 220.269K Nov 12, 2026
DFUS 0.00% 12,368 $ 105.128K Nov 12, 2026
AVUS 0.00% 8,244 $ 61.995K Nov 16, 2026